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Abstract
Objective The purpose of this article is to provide a compre-
hensive review of the imaging features of extracutaneous
melanomas.
Conclusion Extracutaneous melanomas are clinically and bi-
ologically distinct from their more common cutaneous coun-
terpart with higher frequency of metastatic disease and poorer
overall prognosis. Complete surgical excision is the treatment
of choice whenever possible; systemic therapy in the form of
conventional chemotherapeutic agents as well as novel
targeted agents is used for advanced/ metastatic disease. Mul-
tiple imaging modalities including US, CT, MRI and FDG-
PET/CT play important roles in the evaluation of the primary
tumour, assessment of metastatic disease and monitoring re-
sponse to treatment. Radiologists should be aware of the typ-
ical imaging manifestations of extracutaneous melanoma, the
distinct patterns of metastatic involvement as well as treatment
response and toxicities associated with newer molecular
targeted and immunotherapies to optimally contribute to pa-
tient management.
Teaching points
• Mucosal melanoma is clinically and biologically distinct
from cutaneous melanoma.
• Mucosal melanoma has a higher rate of metastatic disease
than the cutaneous subtype.
• Imaging is helpful in assessment of disease and response to
treatment.
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Introduction
Extracutaneous melanomas are rare, aggressive melanomas
that are clinically and biologically distinct from cutaneous
melanoma and include mucosal, ocular and leptomeningeal
melanomas. According to a study based on data from the
North American Association of Central Cancer Registries,
extracutaneous melanomas represent only 5 % of all melano-
ma with approximately 70 % being ocular and rest mucosal
subtypes [1]. Extracutaneous melanoma tends to affect older
patients and is often detected at an advanced stage, with a
worse prognosis than its cutaneous counterpart. Complete sur-
gical excision is the treatment of choice for mucosal melano-
ma, if feasible; systemic therapy is used for metastatic disease.
Knowledge about unique imaging features of extracutaneous
melanoma is important in clinical practice because of its rarity
and adverse prognosis compared to more common cancers
affecting the orbit and various mucosal sites. In this review,
we comprehensively describe the epidemiologic, pathophysi-
ologic and clinical features, diagnostic workup, staging and
management of extracutaneous melanoma with a focus on the
role of imaging. Ocular melanoma, leptomeningeal melanoma
and mucosal sites of origin are discussed.
Differences between cutaneous and mucosal melanoma
Mucosal melanoma is a rare but aggressive form of melanoma
that is clinically and biologically distinct from cutaneous mel-
anoma. Compared with cutaneous melanoma, mucosal mela-
noma has several distinct features. Mucosal melanoma gener-
ally occurs in elderly patients, with a median age at diagnosis
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of 70 years, as opposed to 44 years for cutaneous melanoma.
No clear predisposing factors have been identified for mucosal
melanoma. Cutaneous melanoma is about 16 times more com-
mon among whites than blacks, while mucosal melanoma is
only twice as common. Contrary to cutaneous melanoma,
which is more common in males, mucosal melanoma is more
prevalent in females, with a male-to-female rate ratio of 0.54
[1]. The higher prevalence of mucosal melanoma in the fe-
male population is due to the frequency of vulvovaginal mel-
anoma. Approximately 40 % of mucosal melanomas are
amelanotic and 20 % are multifocal compared with just
10 % and 5 % for cutaneous melanomas, respectively [2].
Mucosal melanoma is often diagnosed late and is associated
with poor outcome, as compared to cutaneous melanoma (5-
year overall survival rate of 25 % compared to 81 % with
cutaneous melanoma) [2]. Complete surgical excision with
clear margins is often difficult to achieve because of the loca-
tion of these tumours and their multifocal nature.
Ocular melanoma
Epidemiology
Ocular melanoma is the most common primary eye tumour in
adults and the second most common type of melanoma after
the cutaneous type. The majority (80 %) of the ocular mela-
nomas originate in the uvea (iris, ciliary body and choroid),
while the remainder arise in non-uveal sites, including the
conjunctiva [1]. The incidence of ocular melanoma increases
with age, peaking near the age of 70 years [3].
Clinical features and diagnostic workup
Uveal melanoma arises from melanocytes of the iris, ciliary
body or the choroid. Choroidal melanoma is the most com-
mon subtype of the uveal melanoma comprising 86 % cases
[1]. Various host factors that may increase the risk of uveal
melanoma include Caucasian race, light skin and eye color,
and propensity to sunburn [4]. Also, atypical cutaneous nevi,
common cutaneous nevi, cutaneous freckles and iris nevi in-
crease the risk of uveal melanoma [5]. The clinical presenta-
tion of uveal melanoma depends on the size and location of
the tumour ranging from asymptomatic incidental detection
on ophthalmic examination to a variety of visual symptoms.
Common clinical features include blurred vision, visual field
defect, floaters, pain and increased intraocular pressure. The
initial diagnosis of uveal melanoma is usually done on fundo-
scopic examination. Ocular ultrasound and fluorescein angi-
ography are useful for further characterisation. The tumour
node metastasis (TNM) staging of uveal melanoma is done
according to the American Joint Committee on Cancer
(AJCC) system [6]. In this system, the extent of the primary
tumour (T), presence or absence of lymph node involvement
(N), and presence or absence of distant metastasis (M) are
used for staging the disease. T staging of iris melanoma is
done according to tumour extent, associated secondary glau-
coma and extraocular ocular extension. Posterior uveal (ciliary
body and choroid) melanoma is graded according to tumour
basal diameter and thickness, ciliary body involvement and
extraocular extension. The regional lymph nodal involvement
is classified as NX (cannot be assessed), N0 (lymph node
metastasis absent) and N1 (lymph node metastasis present).
Similarly, metastatic disease is designated as MX (cannot be
assessed), M0 (distant metastasis absent) and M1 (distant me-
tastasis present). Among subtypes of uveal melanoma, iris
melanoma is associated with a better prognosis than
ciliochoroidal subtype [7]. Primary goals in treating uveal
melanoma are preserving vision if feasible and preventing
metastatic disease. In the past, enucleation was the standard
treatment for uveal melanoma; however, in recent years enu-
cleation has been largely replaced by various forms of radia-
tion therapy (brachytherapy, proton beam irradiation and
Gamma Knife) [8].
Imaging findings
Orbital ultrasound (US) is an excellent modality for evaluation
of ocular melanoma and to differentiate it from with other
entities that may have similar clinical presentation. Both A-
scan and B-scan ultrasonographies are useful in the evaluation
of uveal melanoma. The classical appearance of choroidal
melanoma on B scans is a biconvex echogenic mass
(Fig. 1a). The tumours that have ruptured through Bruch’s
membrane show a collar button configuration [7]. Continuous
expansion of the tumour leads to exudative retinal detach-
ment, subretinal haemorrhage and vitreous haemorrhage. Ul-
trasonography is also useful for detecting scleral invasion and
trans-scleral extension of the tumour. Many ocular lesions
such as choroidal nevus, choroidal metastasis, choroidal
haemangioma, posterior scleritis and age-related macular de-
generation (AMD) can resemble uveal melanoma on imaging
and should be considered in the differential diagnosis.
CT protocol for orbital imaging consists of thin-slice recon-
struction in both soft tissue and high-resolution bone algo-
rithms. On CT, uveal melanoma appears as a hyperdense len-
ticular or mushroom-shaped lesion with post-contrast en-
hancement (Fig. 2). The MRI protocol for orbits includes T2
STIR (short tau inversion recovery), T1 and T1 fat-saturated
TSE (turbo spin echo) sequences with 3-mm slice thickness
and post-contrast fat-saturated T1 images in axial, coronal and
oblique sagittal planes. On MRI, these lesions typically show
characteristic T1 hyperintensity and T2 hypointensity due to
paramagnetic effects of melanin, which causes T1 and T2
shortening (Fig. 3a and b). However, mildly pigmented le-
sions and amelanotic melanomas may be isointense to the
vitreous body on T1-weighted images [9]. MRI is particularly
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useful for evaluation of optic nerve and retrobular soft tissue
because of its superior contrast resolution (Fig. 4a-d). High-
resolution MR imaging with surface coils is accurate for eval-
uating potential extrascleral extension of uveal melanoma,
which can change the management of these tumours [10].
Orbital melanoma is generally first detected on
opthalmoscopic examination. US is usually the first imaging
modality used for further evaluation melanoma and is helpful
in differentiating it from ocular pathologies. Cross-sectional
imaging modalities such as CT and particularly MRI are use-
ful for the exact delineation of the tumour and evaluation of
optic nerve involvement and extraocular extension. PET/CT is
useful for evaluation of metastatic disease, providing a whole-
body evaluation in one session and also for assessment of
treatment response.
Primary malignant melanoma of the CNS
Primary melanoma of the central nervous system is a rare
tumour that accounts for approximately 10 % cases of CNS
melanoma, the rest being metastases to the CNS from other
primary sites [11]. Primary CNS melanoma arises directly
from melanocytes within the leptomeninges, derived from
the neural crest during early embryonic development [12,
13]. Primary melanoma of the CNS may present with ei-
ther localised intra-/extraaxial mass lesions or diffuse men-
ingeal melanomatosis. The discrete mass lesions can be
extraaxial, intracerebral, intraventricular or intramedullary
in locations [11, 14]. Primary intraventricular malignant
melanoma arises from arrested melanocytic cells in the
choroid plexus.
Fig. 1 A 52-year-old female with
uveal melanoma and hepatic me-
tastases. a Grey-scale ultrasound
image showing an echogenic
mass in the posterior segment of
the left globe (arrow). b Axial fat-
suppressed T1-weighted MR im-
age showing hyperintense hepatic
metastatic lesions (arrow). c The
lesions are hypointense on the
corresponding axial fat-
suppressed T2-weighted MR im-
age (arrows)
Fig. 2 A 62-year-old male with
choroidal melanoma. a Axial CT
image shows a hyperdense mass
in the posterior segment of the
right globe (arrow). b The lesion
shows moderate FDG uptake on
the corresponding axial fused
FDG-PET/CT image (arrow)
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On imaging, primary CNS melanoma is indistinguishable
from metastatic melanoma and is usually a diagnosis of ex-
clusion after ruling out primary sites involving the skin, eyes
and mucosal surfaces. The lesions are generally hyperdense
on CT and show T1 hyperintense and T2 iso-hypointense
signal on MRI with variable enhancement on post-contrast
sequences (Fig. 5). [15]. Localised leptomeningeal melano-
ma can mimic meningiomas and acoustic neuromas, with
definitive diagnosis made only on histopathological exami-
nation. Primary diffuse meningeal melanomatosis shows dif-
fuse dural leptomeningeal thickening and enhancement on
CT/MRI [16].
Fig. 3 A 46-year-old male with uveal melanoma. aOn the axial T1-weightedMR image of the brain, there is a T1 hyperintense choroidal mass (arrow).
b The mass is hypointense on the corresponding axial T2-weighted MR image (arrow)
Fig. 4 A 26-year-old male with ocular melanoma with extraocular ex-
tension and intracranial metastases. a Axial T1-weighted MR image
showing a heterogeneous mass involving the right orbit with areas of
T1 hyperintensity (arrow) and extraocular extension. b The mass is het-
erogeneously hypointense on the corresponding axial T2-weighted MR
image (arrow). c On corresponding axial diffusion-weighted MRI, the
mass shows restricted diffusion (arrow). d Axial contrast-enhanced T1-
weighted MR image shows heterogeneous enhancement of the lesion
(arrow). e Axial T2-weighted MR image shows metastatic lesions in the
frontal lobes showing T2 hypointensity (arrows) with surrounding
vasogenic edema. f The lesions are hyperintense on the corresponding
axial T1-weighted MR image of the brain (arrows). g On the correspond-
ing axial susceptibility-weighted (SW) MRI the lesions are hypointense
(arrows) confirming a haemorrhagic component
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Mucosal melanoma
Epidemiology
Mucosal melanoma arises from the mucosal epithelium of the
respiratory, gastrointestinal and genitourinary tracts and ac-
counts for 1 to 2 % of melanoma [17]. Mucosal melanoma
usually occurs in middle-aged and elderly patients with a
median age of 70 years. Approximately 30 % of mucosal
melanomas are multifocal [18]. The head and neck region
is the most common site of mucosal melanoma in males
and the second most common site in females, accounting
for approximately 25 to 50 % of all cases of mucosal mela-
noma [1]. The incidence rate for mucosal melanoma arising
from the genital tract, rectum and anal canal is higher in
females compared to males.
Clinical features, staging and diagnostic workup
Mucosal melanomas include head and neck, vulvovaginal,
anorectal and urinary tract melanomas. More than 50 % of
cases of mucosal melanoma arise from head and neckmucosal
surfaces. The nasal cavity is the most common head and neck
site for mucosal melanoma followed by the oral cavity [1].
Less frequent sites in the head and neck region include the
pharynx, larynx and oesophagus. Clinically mucosal melano-
mas arising from the nasal cavity and paranasal sinuses pres-
ent with nasal obstruction, epistaxis and anosmia [19]. Oral
mucosal melanoma is frequently detected as mucosal pigmen-
tation, bleeding or ulceration [20]. The genital tract is the most
common site of mucosal melanoma in females, responsible for
more than 50 % cases [1]. In females, the vulva is the most
common site for genitourinary melanoma, followed by the
vagina. Anorectal mucosal melanoma represents approxi-
mately 0.05 percent of all colorectal malignancies [21]. The
rectum is the most common site (42 %), followed by the anal
canal (33 %) and overlapping areas (25 %) [21]. HIV infection
increases the risk of anorectal melanoma [22].
In 2010, the AJCC developed a specific TNM staging sys-
tem for head and neck mucosal melanoma. According to the
AJCC, staging of mucosal melanomas of the head and neck is
done according to the tumour, node and metastasis (TNM)
classification with disease confined to the mucosa designated
as T3 to reflect their aggressiveness (Table 1) [23]. Contrary to
head and neckmucosal melanoma, there is no universal staging
system for anorectal and vaginal melanoma. The Ballantyne
staging system, which was originally developed to stage head
and neck melanomas, is generally used to stage anorectal and
vaginal melanomas (Table 2) [2, 24, 25]. The AJCC-2002 stag-
ing system for cutaneous malignant melanoma is used to stage
vulvar melanoma and is the most significant predictor of
recurrence free survival (Table 3) [26]. The diagnostic workup
for mucosal melanoma includes endoscopic examination and
various imaging modalities including CT, MRI and PET/CT.
CT and/or MRI are used for evaluation of the primary site of
disease in various mucosal melanomas, for delineation of local
extent of disease and regional lymph nodal involvement. MRI
Fig. 5 A 54-year-old female with
choroidal melanoma. a Axial T2-
weighted MR image showing an
intraventricular mass lesion with
T2 shortening involving the left
lateral ventricle (arrow). b On the
corresponding axial contrast-
enhanced T1-weighted MR im-
age, the lesion shows avid en-
hancement (arrow)




T4a: Moderately advanced disease. Tumour involving deep soft tissue,
cartilage, bone or overlying skin
T4b: Very advanced disease. Tumour involving brain, dura, skull base,
lower cranial nerves (IX, X, XI,XII), masticator space, carotid artery,
prevertebral space or mediastinal structures
Regional lymph nodes (N)
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph node metastases
N1: Regional lymph node metastases present
Distant metastasis (M)
M0: No distant metastasis
M1: Distant metastasis present
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is particularly useful in differentiating melanoma from other
tumours because of its high soft tissue resolution and ability
to depict characteristic T1 hyperintensity and T2 hypointensity
of melanin. Evaluation of lymph node involvement and meta-
static disease is usually done byCTor PET/CT. CTand/or PET/
CT is also used for assessment of response to treatment.
Imaging findings
Head and neck mucosal melanoma Most frequent sites of
head and neck mucosal melanoma are mucosa of nasal cavity,
oral cavity and paranasal sinuses [27]. Among sinonasal mel-
anoma the most common sites of origin are the nasal septum,
lateral nasal wall, paranasal sinuses, and the inferior and mid-
dle turbinates. Within the oral cavity, the upper alveolus and
hard palate are frequent sites. Sometimes the origin of the
primary tumour is difficult to assess because of the large size
and multifocal nature of the tumour. Lymph node metastases
are seen in up to 25 % of patients at presentation, mostly
involving the submandibular and upper jugular groups [28].
Lymph node metastases are less common in sinonasal mela-
noma in comparison with oral mucosal melanomas [27]. Ad-
verse prognostic factors in head and neck mucosal melanomas
are clinical stage at presentation, tumour thickness greater
than 5 mm, vascular invasion and distant metastases [27].
The CT appearance of sinonasal melanoma is nonspecific
and consists of a mass lesion with contrast enhancement and
adjacent osseous destruction (Fig. 6a). The MRI appearance
depends on the histological features of the lesion (melanotic
verus amelanotic) and presence of haemorrhage within the
lesion [29]. Melanotic melanomas typically exhibit T1
hyperintensity and an intermediate-hypointense pattern on
T2-weighted MRI. Amelanotic melanomas are generally
hypointense on T1- and hyperintense on T2-weighted se-
quences. The lesions demonstrate mild to moderate enhance-
ment on gadolinium-enhanced MRI [29]. The differential di-
agnosis of T1 hyperintense lesions includes haemorrhage in
primary nasal lesions such as haemangioma and juvenile
angiofibroma, proteinaceous secretions in mucoceles, fat-
containing lesions and haemorrhagic metastases.
Vulvovaginal melanoma Vulvar melanoma is the most com-
mon site for genital melanoma accounting for 76 % of cases,
followed by vaginal melanoma (20 %) [1]. Melanoma is the
second most common vulvar malignancy after squamous cell
carcinoma. CT findings in genital melanoma are nonspecific
and consist of enhancing mass lesion(s) and invasion into
surrounding organs (Fig. 7a). Genital melanoma shows iso-
to hyperintense signal on T1-weighted MRI and usually hy-
perintense signal on T2-weighted images. Apart from conven-
tional MRI sequences, dynamic contrast-enhanced MRI and
diffusion-weighted imaging (DWI) are also useful in the eval-
uation of melanoma. On DWI, vaginal melanoma exhibits
hyperintense signal with a low apparent diffusion coefficient
(ADC) value. On dynamic post-contrast images, they show a
rapid rise type curve with significant enhancement during the
early phase due to the hypervascular nature of these tumours
[30]. The differential diagnosis for genital melanoma includes
epithelial as well as various non-epithelial tumours such as
lymphoma, leiomyosarcoma and schwannoma.
Anorectal melanoma is usually seen as an intraluminal pol-
ypoid or fungating mass in the distal rectum or anal canal.
Perirectal infiltration of the tumour is characterised by exten-
sion to the pelvic side wall and the pre-sacral space. Lymph
node spread is commonly seen at presentation and occurs in the
perirectal, internal iliac, obturator and inguinal groups. Luminal
obstruction is less common in anorectal melanoma [31]. The
main differential diagnosis for anorectal melanoma is adenocar-
cinoma, which is frequently seen as an obstructive mass be-
cause of infiltration and narrowing of the lumen. MRI is par-
ticularly useful for preoperative staging in anorectal melanoma
patients, in particular to assess bowel wall invasion, because of
Table 2 Ballantyne
staging system Stage Disease extent
I Clinically localised disease
II Regional nodal involvement
III Distant metastatic disease
Table 3 (AJCC) TNM staging system of vulvar melanoma
Primary tumour (T)
TX: Primary (main) tumour cannot be assessed
T0: No evidence of primary tumour
Tis: Melanoma in situ
T1: The melanoma is less than or equal to 1.0 mm thick
T2: The melanoma is between 1.01 and 2.0 mm thick
T3: The melanoma is between 2.01 and 4.0 mm thick
T4: The melanoma is thicker than 4.0 mm
T1-T4 stages are subdivided into a (without ulceration) and b (with
ulceration)
Regional lymph nodes (N)
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph node metastases
N1: Spread to 1 nearby lymph node
N2: Spread to 2 or 3 nearby lymph nodes, OR spread of melanoma to
nearby skin (known as satellite tumours) or toward a nearby lymph
node area (known as in-transit tumours) without reaching the lymph
nodes
N3: Spread to 4 or more lymph nodes, OR spread to lymph nodes that are
clumped together, OR spread of melanoma to nearby skin (satellite
tumours) or toward a lymph node area and into the lymph node(s)
Distant metastasis (M)
M0: No distant metastasis
M1a: Metastasis to skin, subcutaneous tissue or lymph nodes in distant
parts of the body, with a normal blood LDH level
M1b: Metastasis to the lungs, normal LDH level
M1c:Metastasis to other organs or distant spread to any site alongwith an
elevated blood LDH level
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its superior contrast resolution compared to CTand multiplanar
imaging capacity. Similar to other sites, anorectal melanomas
are hyperintense on T1-weighted images and show mixed sig-
nal intensity on T2-weighted images (Fig. 8a) with marked
enhancement on post-contrast T1-weighted images (Fig. 8b);
however, amelanotic melanomas, which comprise approxi-
mately 10 to 29 % of anorectal melanomas, are hypointense
on T1- and hyperintense on T2-weighted sequences [32].
Fig. 6 A 73-year-old male with
metastatic sinonasal melanoma on
treatment with BRAF and MEK
inhibitors. a Coronal contrast-
enhanced CT image shows a ho-
mogeneous mass lesion involving
the right nasal cavity (arrow). b
Sagittal contrast-enhanced CT
image before the start of chemo-
therapy shows a large small bowel
metastatic lesion (arrow). c Sagit-
tal contrast-enhanced CT image
after four cycles of chemotherapy
shows a significant interval de-
crease in the size of the metastatic
lesion and new left moderate
pleural effusion (arrowhead)
Fig. 7 A 63-year-old female with
vaginal melanoma and pancreatic
and hepatic metastases. a Axial
contrast-enhanced CT image
shows heterogeneously enhanc-
ing vaginal mass (arrow). b Axial
contrast-enhanced CT image
shows a heterogeneous mass in-
volving the pancreatic head
(arrow) and an ill-defined
hypointense lesion in the right
lobe of the liver (arrowhead). c
On corresponding axial diffusion-
weighted MRI, the lesions show
restricted diffusion. d Axial
contrast-enhanced fat-suppressed
T1-weighted MR image shows
pancreatic (arrow) and hepatic
(arrowhead) metastatic lesions
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Metastatic disease
Up to 95% of patients with mucosal melanoma havemetastatic
disease at presentation or develop it during the course of their
disease [33]. Common sites of metastatic disease are the lung,
liver, peritoneum and central nervous system. Less common
sites of metastatic disease include the skin, subcutaneous tis-
sues and bones. Approximately 50 % of all patients with pri-
mary uveal melanoma will develop metastatic disease [8]. The
liver is the most commonly involved site of metastases in ap-
proximately 90 % of patients with ocular melanoma. Common
extrahepatic sites of metastases are the lung, bone and skin [8].
Pattern of metastases in mucosal melanoma
The pattern of metastases depends upon the primary site of
mucosal melanoma. Vaginal melanoma has a predilection for
early peritoneal tumour spread because of the close anatomic
relationship of the vagina to the peritoneal surface (Fig. 9)
[33]. In many patients with vulvovaginal melanoma, distant
metastatic disease can develop even in the absence of regional
lymph node involvement (Fig. 7b-d). Sinonasal melanomas
commonly metastasise to the liver. Lymph node spread is seen
in approximately 60 % cases of anorectal melanoma [28].
Anal melanoma commonly spreads to the inguinal lymph
nodes because of the lymphatic drainage to that site [33].
Common sites of distant metastases for head and neck mela-
noma are the lung, liver, bone and brain.
Imaging in metastatic disease
Assessment of metastatic disease in extracutaneous melanoma
is done with various imaging modalities including radiography,
US, CT, MRI and PET/CT, each having its advantages and
limitations. Contrast-enhanced MRI is the gold standard for
evaluation of metastatic involvement of brain. The role of
PET/CT for evaluation of brain metastases is somewhat limited
because of background cerebral metabolic activity [34]. The
typical appearance of metastatic intracerebral melanoma on
MRI is lesions of high signal intensity on T1-weighted images
and low signal intensity on T2-weighted images, seen in ap-
proximately 50 % patients, because of the effects of both free
radicals in melanin as well as a haemorrhagic component
(Fig. 4e-g) [35]. MRI is also the modality of choice for the
detection and characterisation of metastatic liver lesions be-
cause of its higher contrast resolution and lack of ionising ra-
diation (Fig. 1b and c). US is helpful for differentiating between
solid and cystic liver lesions; however it has inferior sensitivity
Fig. 8 A 76-year-old male with
anorectal melanoma. a Sagittal
T2-weighted MR image shows a
heterogeneous mass lesion arising
from the anterior wall of the rec-
tum (arrow). b The mass shows
enhancement on the correspond-
ing sagittal fat-suppressed T1-
weighted MR image (arrow)
Fig. 9 A 61-year-old female with
vaginal melanoma and peritoneal
metastasis. Axial unenhanced CT
(a) and fused FDG-PET/CT (b)
images show diffuse peritoneal
thickening (arrows in a) with in-
tense FDG uptake (arrows in b).
Axial unenhanced CT (c) and
fused FDG-PET/CT (d) images
after treatment with imatinib
shows a significant decrease in
peritoneal thickening (arrows in
c) and FDG uptake (arrows in d)
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and specificity compared to CTorMR imaging. OnCT, hepatic
metastases are often hypervascular and usually show enhance-
ment during the late arterial phase and become hypoattenuating
to background liver parenchyma in the portal venous phase [36,
37] . CT is also the most sensitive imaging modality for pul-
monary metastases [38]. PET/CT is becoming increasingly
popular in the staging of metastatic extracutaneous melanoma.
Because malignant cells usually have a higher metabolic rate,
they show greater FDG avidity than adjacent normal tissues.
PET-CToften helps in treatment planning based on the stage of
disease as it provides evaluation of various metastasis sites in a
single examination (Fig. 9a-d).
Prognosis of mucosal melanoma depends upon the primary
site and stage of the disease, with melanomas of the oral cavity
and external genitalia having a better prognosis as compared
to other mucosal locations [17]. The prognosis of pharyngeal,
gastroesophageal and vaginal melanoma is usually poor. The
long-term prognosis of anorectal melanoma is poor, with over-
all 5-year survival of about 15 to 20 %, even in patients with
surgically resectable disease at presentation [2]. Lymph nodal
involvement and presence of distant metastases at presentation
are adverse prognostic factors and associated with poor over-
all survival. Surgery is the primary treatment for mucosal mel-
anomas if the lesion can be resected with negative margins;
however, complete surgical resection with adequatemargins is
often not possible. In these cases and advanced disease, sys-
temic treatment becomes important [39, 40].
Systemic treatment for advanced stage extra-cutaneous
melanoma and recent treatment advances
Systemic treatment of patients with metastatic melanoma aris-
ing from mucosal and uveal primaries is largely based on the
experience on systemic treatment of metastatic cutaneous mel-
anoma. Commonly used cytotoxic drugs in patients with met-
astatic melanoma include dacarbazine, temozolamide,
interleukin-2 and paclitaxel. In the past few years, major ad-
vances have been made in the molecular understanding of mel-
anoma with identification of multiple oncogenes and develop-
ment of small molecular targeted therapies against them [41].
BRAF is the most commonly mutated oncogene in malig-
nant melanoma, and the BRAF mutation is seen in approxi-
mately 50 % of cutaneous melanomas [42]. BRAF mutations
are seen in about 10 % of mucosal melanomas. Vemurafenib
and dabrafenib are inhibitors of mutated BRAF signaling.
Trametinib is an orally active small molecule inhibitor of
MEK1 and MEK2 in the mitogen-activated protein kinase
(MAPK) signal transduction pathway. Sequential inhibition
of the MAPK pathway by combination therapy with
dabrafenib (a selective BRAF inhibitor) and trametinib
(MEK inhibitor) has been shown to improve the
progression-free survival in patients with BRAF V600 mela-
noma (Fig. 6b and c) [43]. The US Food and Drug Adminis-
tration (FDA) has approved drugs for BRAF mutant melano-
ma including the BRAF inhibitors vemurafenib (August
2011) and dabrafenib (May 2013) as well as the MEK inhib-
itor trametinib (May 2013).
Uveal melanoma has a different molecular pathogenesis
compared with cutaneous and mucosal melanoma. Mutations
in BRAF, KIT and NRAS are rarely seen in uveal melanoma;
however more than 80 percent of uveal melanomas have mu-
tations in GNAQ or GNA11. The GNAQ and GNA11 muta-
tions lead to the activation of the downstream MAPK path-
way, which may be a potential target for therapeutic interven-
tion [44]. According to a phase 2 clinical trial in patients with
metastatic uveal melanoma, treatment with selumetinib (a
Fig. 10 A 57-year-old female
with metastatic melanoma from
anorectal primary on treatment
with ipilimumab. a Axial
contrast-enhanced CT image be-
fore the start of chemotherapy
shows a large heterogeneous
paracardiac mediastinal mass (ar-
row). b Axial contrast-enhanced
CT image 1 month after the start
of treatment shows an increase in
the size of the mass, however with
a decrease in enhancement (ar-
row). c Axial contrast-enhanced
CT image 1 month after comple-
tion of treatment shows a decrease
in the size and enhancement of the
mass (arrow)
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selective inhibitor of MEK1 and MEK2) resulted in a mod-
estly improved progression-free survival and response rate
compared with chemotherapy [45]. Mucosal melanomas have
an increased prevalence of c-KIT mutations, seen in about 20-
25 % cases [41]. Imatinib is a small molecule inhibitor of KIT
that inhibits proliferation and induces apoptosis in melanoma
cells harbouring KIT mutations, associated with significant
clinical response in these patients [46].
Ipilimumab is a monoclonal antibody that was approved for
the treatment of metastatic cutaneous melanoma by the FDA in
March 2011. In recent clinical trials, ipilimumab has also been
found useful in patients with metastatic uveal and mucosal
melanomas [25, 47]. Ipilimumab activates the immune system
by targeting cytotoxic T-lymphocyte-associated protein 4
(CTLA-4). CTLA-4 is a key downregulator of the immune
system and blockade of CTLA-4 potentiates the T cell-
mediated anti-tumour immune response [48]. Inhibition of
CTLA-4 by ipilimumab can lead to unique immune-related
adverse events (irAEs) such as a rash, colitis, hepatitis,
hypophysitis, thyroiditis and pancreatitis [49]. Because of the
distinct biologic mechanism of immunotherapeutic agents,
immune-related response criteria (irRC) have been developed
to characterise additional recognised patterns of treatment re-
sponse. There are four distinct response patterns associated
with favorable survival: (1) shrinkage in baseline lesions, with-
out new lesions; (2) durable stable disease; (3) response after an
initial increase in total tumour burden; (4) response in the pres-
ence of new lesions (Fig. 10). Detailed discussion about organ-
specific irAEs and irRC is beyond the scope of this article [50].
Pembrolizumab and nivolumab are newer generation immuno-
therapy drugs, which were recently granted accelerated FDA
approval in September and December 2014, respectively.
Pembrolizumab and nivolumab have higher response rates
and less toxicity compared to ipilimumab.
Conclusion
In conclusion, extracutaneous melanomas are clinically and
biologically distinct from cutaneous melanomas because of
the higher frequency of metastatic disease and poorer overall
prognosis. Complete surgical excision is the treatment of choice
whenever possible; systemic therapy in the form of convention-
al chemotherapeutic agents as well as novel targeted agents is
used for advanced/metastatic disease. Multiple imaging modal-
ities including US, CT, MRI and FDG-PET/CT play important
roles in the evaluation of the primary tumour, assessment of
metastatic disease and monitoring response to treatment. Radi-
ologists should be aware of the typical imaging manifestations
of extracutaneous melanoma, the distinct patterns of metastatic
involvement, as well as treatment response and toxicities asso-
ciated with newer molecular targeted and immunotherapies to
optimally contribute to patient management.
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